# Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

> **NCT05059522** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 68 (actual)

## Conditions studied

- Advanced Malignancies
- NSCLC
- Ovarian Cancer
- Urothelial Cancer
- Solid Tumors

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Lorlatanib
- **DRUG:** Talazoparib
- **DRUG:** Pemetrexed
- **DRUG:** Axitinib
- **DRUG:** CMP 001
- **DRUG:** Utomilumab
- **DRUG:** PF04518600

## Key facts

- **NCT ID:** NCT05059522
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-29
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059522, "Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05059522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*